Singh M, Zuo J, Li X, Ambrus G, Lei Z M, Yussman M A, Sanfilippo J S, Rao C V
Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Kentucky 40292, USA.
Biol Reprod. 1995 Sep;53(3):591-7. doi: 10.1095/biolreprod53.3.591.
Human myometrium contains functional hCG/LH receptors. The purpose of this study was to determine whether or not leiomyomas that arise from myometrium also contain these receptors. Northern blotting demonstrated that leiomyomas and normal adjacent myometria contained hCG/LH receptor mRNA transcripts. Western immunoblotting showed that leiomyomas and corresponding normal myometria also contained 60- and 50-kDa receptor proteins. Ligand blotting revealed that only the 50-kDa receptor protein in leiomyomas and corresponding normal myometria could bind 125I-hCG and that this binding inhibited by excess unlabeled hCG. In situ hybridization and immunocytochemistry revealed that smooth muscle cells in leiomyomas and corresponding normal myometria contained the hCG/LH receptor mRNA transcripts and receptor proteins. The receptor levels were lower in leiomyomas than in corresponding normal myometria. However, the receptors were functional, as treatment with hCG resulted in a decrease of connexin-43 protein levels in leiomyomas as in normal myometria. In summary, human uterine leiomyomas express a functional hCG/LH receptor gene at a reduced level compared with that for normal corresponding myometria. This finding could be relevant to an understanding of the growth control mechanisms in leiomyomas and the manner in which medical therapy for leiomyomas might work.
人子宫肌层含有功能性人绒毛膜促性腺激素/促黄体生成素(hCG/LH)受体。本研究的目的是确定源自子宫肌层的平滑肌瘤是否也含有这些受体。Northern印迹法表明,平滑肌瘤和相邻的正常子宫肌层含有hCG/LH受体mRNA转录物。蛋白质免疫印迹法显示,平滑肌瘤和相应的正常子宫肌层也含有60 kDa和50 kDa的受体蛋白。配体印迹法显示,平滑肌瘤和相应正常子宫肌层中只有50 kDa的受体蛋白能结合125I-hCG,且这种结合可被过量未标记的hCG抑制。原位杂交和免疫细胞化学显示,平滑肌瘤和相应正常子宫肌层中的平滑肌细胞含有hCG/LH受体mRNA转录物和受体蛋白。平滑肌瘤中的受体水平低于相应的正常子宫肌层。然而,这些受体是有功能的,因为与正常子宫肌层一样,用hCG处理会导致平滑肌瘤中连接蛋白43的蛋白水平降低。总之,与相应的正常子宫肌层相比,人子宫平滑肌瘤以较低水平表达功能性hCG/LH受体基因。这一发现可能有助于理解平滑肌瘤的生长控制机制以及治疗平滑肌瘤的药物作用方式。